Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe Approvals Drug Review

EU Moment of Truth For Abaloparatide & Advanced Therapy Tab-Cel

  • News

Executive Summary

Radius’s abaloparatide, which was previously rejected by the European Medicine Agency, is among the latest products that are this week being considered for EU-wide marketing approval by the agency.

You may also be interested in...



Dengue Vaccine Qdenga & Nine Drugs Win EMA Thumbs Up

The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.

Mirum Awaits EMA Verdict On ‘Reprioritized’ Livmarli Filing

Mirum could soon find out if its decision to reprioritize its EU filings for its rare liver disease drug has paid off.

Mirum Awaits EMA Verdict On ‘Reprioritized’ Livmarli Filing

Mirum could soon find out if its decision to reprioritize its EU filings for its rare liver disease drug has paid off.

Table

View full table

Topics

Related Companies

Tags:
Europe Approvals Drug Review
Latest Headlines

The Next Big PBM Deal? Rumored Cigna-Humana Talks Raise Overlap Question

Clinical Trial Diversity Plans: Early Oncology Experience Shows More Work Needed, US FDA Says

Pink Sheet Podcast: CAR-T Malignancy Reports, Background Music In DTC Ads, New No. 2 At US FDA

‘Vast Amount Of Valuable Input’ Leads Australia To Extend HTA Review

See All
UsernamePublicRestriction

Register

PS147138

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By